Wat is de prijs voor EFFECTOR Therapeutics, Inc. (EFTRW)

Het prijs van EFFECTOR Therapeutics, Inc. (EFTRW) is $0.0006

Wat is de marktkapitalisatie voor EFFECTOR Therapeutics, Inc. (EFTRW)

Marktkapitalisatie voorEFFECTOR Therapeutics, Inc. (EFTRW) is $2.82K

EFFECTOR Therapeutics, Inc. (EFTRW) Omzet

eFFECTOR Therapeutics, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective translation regulator inhibitors aimed at combating cancer. Their primary investigational drug, Tomivosertib, is an orally administered small-molecule MNK inhibitor currently undergoing Phase 2b clinical trials. This candidate is being evaluated for its efficacy in patients suffering from metastatic non-small cell lung cancer. Additionally, the company is advancing zotatifin, another small molecule engineered to block eukaryotic initiation factor 4A (eIF4E). Zotatifin is presently in Phase 1/2 clinical studies for individuals with various solid tumors. Furthermore, it's being tested in a Phase 2a open-label expansion cohort, in conjunction with fulvestrant and abemaciclib, for patients afflicted with ER-positive breast cancer. eFFECTOR Therapeutics, Inc. also holds a research collaboration and licensing pact with Pfizer Inc., focused on co-developing eIF4E inhibitors. Established in 2012, the company maintains its corporate headquarters in Solana Beach, California.

Jaar	Omzet	Wijzigen
Niet genoeg gegevens voor de verstrekte datums.

Jaar

Omzet

Wijzigen

Niet genoeg gegevens voor de verstrekte datums.

Bedrijf	Omzet	Omzetverschil	Land
Vertex Pharmaceuticals Incorporated VRTX.US	$12.62B	-	US
Argenx SE ARGX.US	$6.02B	-	NL
Lonza Group AG LONN.SW	-	-	CH
UCB S.A. UCB.BR	$10.11B	-	BE
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR

Bedrijf

Omzet

Omzetverschil

Land